The discovery of chlordiazepoxide and the clinical introduction of benzodiazepines: Half a century of anxiolytic drugs

Journal of Anxiety Disorders

Volumn 25, Issue 4, 2011, Pages 554-562

  López Muñoz, Francisco ^a,b   Álamo, Cecilio ^a   García García, Pilar ^a  

^a UNIVERSITY OF ALCALÁ   (Spain)

^b CAMILO JOSÉ CELA UNIVERSITY   (Spain)

Author keywords

Anxiolytic drugs; Benzodiazepines; Chlordiazepoxide; History of psychiatry

Indexed keywords

4 AMINOBUTYRIC ACID RECEPTOR; ALPRAZOLAM; ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; BARBITAL; BARBITURIC ACID DERIVATIVE; BENZODIAZEPINE DERIVATIVE; BENZODIAZEPINE RECEPTOR; CHLORDIAZEPOXIDE; DIAZEPAM; MEPROBAMATE; OXAZEPAM; PHENOBARBITAL; PLACEBO; TRIAZOLAM;

ANXIETY DISORDER; ARTICLE; AWARENESS; DROWSINESS; DRUG ABUSE; DRUG CHOICE; DRUG CONTROL; DRUG DEPENDENCE; DRUG EFFICACY; DRUG MISUSE; DRUG OVERDOSE; DRUG RESPONSE; DRUG SAFETY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TOLERANCE; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FATALITY; GABAERGIC SYSTEM; HUMAN; INTELLECT; MUSCLE RELAXATION; NEUROSIS; NONHUMAN; SEDATION; SELF MEDICATION; SIDE EFFECT; TRANQUILIZING ACTIVITY; UNSPECIFIED SIDE EFFECT;

EID: 79953687656     PISSN: 08876185     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.janxdis.2011.01.002     Document Type: Article

References (89)

1. Álamo C., López-Muñoz F., Echániz T., Cuenca E. Fármacos ansiolíticos, sedantes e hipnóticos. Historia de la Neuropsicofarmacología. Una nueva aportación a la terapéutica farmacológica de los trastornos del Sistema Nervioso Central 1998, 245-268. Ediciones Eurobook, Madrid. F. López-Muñoz, C. Álamo (Eds.).
2. Awapara J., Landua A., Fuerst R., Seale B. Free gamma-aminobutyric acid in brain. Journal of Biological Chemistry 1950, 187:35-39.
3. Ayd F.J. The early history of modern psychopharmacology. Neuropsychopharmacology 1991, 5:71-84.
4. Balme R. Early medicinal uses of bromides. Journal of the Royal College of Physicians 1976, 10:205-208.
5. Balter M.B., Levine J., Manheimer D.L. Cross National Study of the extent of antianxiety/sedative drug use. New England Journal of Medicine 1974, 290:769-774.
6. Ban T.A. Pharmacotherapy of mental illness. A historical analysis. Progress in Neuro-Psychopharmacology & Biological Psychiatry 2001, 25:709-727.
7. Bänninger A., Costa E., Silva J.A., Hindmarch I., Moeller H.J., Rickels K. Good chemistry - the life and legacy of Valium Inventor Leo Sternbach 2004, Mc Graw-Hill, New York.
8. Bargmann E., Wolfe S.M., Levin J. Stopping Valium 1982, Public Citizen Health Research Group, Washington.
9. Barlow D.H., Hersen M. Single-case experimental designs. Uses in applied clinical research. Archives of General Psychiatry 1973, 29:319-325.
10. Bazemore A., Elliott K.A., Florey E. Factor I and gamma-aminobutyric acid. Nature 1956, 178:1052-1053.
11. Bech P. Fifty years with the Hamilton Scales for anxiety and depression. Psychotherapy and Psychosomatics 2009, 78:202-211.
12. Berger F.M. The anticonvulsant activity of carbamate esters of certain of 2,2-disubstituted-1,3-propanediols. Journal of Pharmacology and Therapy 1952, 104:229.
13. Berney P., Halperin D., Tango R., Daeniker-Dayer I., Schulz P. A major change of prescribing pattern in absence of adequate evidence: benzodiazepines versus newer antidepressants in anxiety disorders. Psychopharmacology Bulletin 2008, 41:39-47.
14. Bloom F.E., Iversen L.L. Localizing 3H-GABA in nerve terminals of rat cerebral cortex by electron microscopic autoradiography. Nature 1971, 229:628-630.
15. Bowes H.A. The role of Librium in an outpatient psychiatric setting. Diseases of Nervous System 1960, 21(Suppl. 3):20-22.
16. Braestrud C., Albreschtsen R., Squires R.F. High densities of benzodiazepines receptors in human cortical areas. Nature 1977, 269:702-704.
17. Bury M. Caveat venditor: social dimensions of a medical controversy. Psychotropic drug development. Social, economic and pharmacological aspects 1996, 41-57. Chapman & Hall Medical, London. D. Healy, D.P. Doogan (Eds.).
18. Caldwell A.E. History of psychopharmacology. Principles of psychopharmacology 1970, 9-30. Academic Press, New York. W.G. Clark, J. Del Giudice (Eds.).
19. Cohen I.M. The benzodiazepines. Discoveries in biological psychiatry 1984, 130-141. Ayd Medical Communications, Baltimore. F.J. Ayd, B. Blackwell (Eds.).
20. Cossa P. Thérapeutiques neurologiques et psiquiatriques 1945, Masson & Cie, Paris.
21. Costa E., Greengard P. Mechanism of action of benzodiazepines 1975, Raven Press, New York.
22. Department of Health and Social Security Advisory Council on the Misuse of Drugs. (1982). Treatment and rehabilitation. London: HMSO.
23. Department of Health. (1991). Drug misuse and drug dependence: guidelines on clinical management. London: HMSO.
24. Dubovsky S.L. Approaches to developing new anxiolytics and antidepressants. Journal of Clinical Psychiatry 1993, 54(Suppl. 5):75-83.
25. Dupont J. Histoire de la neurotransmission 1999, Presses Universitaires de France, Paris.
26. Editorial. (1973). Benzodiazepines: use, overuse, misuse, abuse. The Lancet, i, 1101-2.
27. Eisler R.M., Hersen M., Miller P.M., Wooten L.S. Treatment expectations of psychiatric inpatients and their relationship to psychiatric diagnosis. Journal of Clinical Psychology 1973, 29:251-253.
28. Eysenck H.J. The effects of psychotherapy: an evaluation. Journal of Consulting and Clinical Psychology 1952, 16:319-324.
29. Fangmann P., Assion H.J., Juckel G., Álamo C., López-Muñoz F. Half a century of antidepressant drugs. On the clinical introduction of monoamine oxidase inhibitors, tricyclics and tetracyclics. Part II: Tricyclics and tetracyclics. Journal of Clinical Psychopharmacology 2008, 28:1-4.
30. Fava G.A. Unmasking special interest groups: the key to addressing conflicts of interest in medicine. Psychotherapy and Psychosomatics 2010, 79:203-207.
31. Fisher E., von Mering J. Uber ein neue Klasse von Schlafmitteln. Therapie Gegenwart 1903, 44:97-101.
32. Gossop M. The La Roche affair. Living with drugs 1993, 53-55. Ashgate, London. M. Gossop (Ed.).
33. Greenblatt D.J., Shader R.I. Meprobamate: a study of irrational drug use. American Journal of Psychiatry 1971, 127:1297-1303.
34. Greenblatt D.J., Shader R.I. Pharmacotherapy of anxiety with benzodiazepines and beta-adrenergic blockers. Psychopharmacology: a generation of progress 1978, 1381-1390. Raven Press, New York. A. Lipton, A. DiMascio, K.F. Killan (Eds.).
35. Greenblatt D.J., Shader R.U. Dependence, tolerance and addiction to benzodiazepines: clinical and pharmacokinetic considerations. Drug and Metabolism Review 1978, 8:13-28.
36. Guidotti A., Toffano G., Costa E. An endogenous protein modulates the affinity of GABA and benzodiazepine receptors in rat brain. Nature 1978, 275:553-555.
37. Harris T.H. Methaminodiazepoxide. Journal of the American Medical Association 1960, 172:128-129.
38. Healy D. The creation of psychopharmacology 2002, Harvard University Press, Cambridge.
39. Hersen M. Limitations and problems in the clinical application of behavioral techniques in psychiatric settings. Behavior Therapy 1979, 10:65-80.
40. Hersen M. Behavioral assessment and psychiatric diagnosis. Behavioral Assessment 1988, 10:107-121.
41. Hesbacher P.T., Rickels K., Hutchison J., Raab E., Sablosky L., Whalen E., et al. Setting, patient, and Doctor effects on drug response in neurotic patients: I. Differential attrition, dosage deviation, and side reaction responses to treatment. Psychopharmacology 1970, 18:180-208.
42. Jacobsen E. The early history of psychotherapeutic drugs. Psychopharmacology 1986, 89:138-144.
43. Johns M.W. Self-poisoning with barbiturics in England and Wales during 1959-74. British Medical Journal 1977, i:1128-1130.
44. Kuffler S.W., Edwards C. Mechanism of gamma-aminobutyric acid (GABA) action and its relation to synaptic inhibition. Journal of Neurophysiology 1958, 21:589-610.
45. Lader M.H. Benzodiazepines: the opium of the masses?. Neuroscience 1978, 3:159-165.
46. Lader M.H. Epidemic in the making: benzodiazepine dependence. Epidemiological impact of psychotropic drugs 1981, 313-324. Elsevier/North-Holland Biomedical Press, Amsterdam. G. Tognoni, C. Bellantuono, M. Lader (Eds.).
47. Locock C. Comment in discussion of Edward H. Sieveking. Analysis of fifty-two cases of epilepsy. The Lancet 1857, ii:136-138.
48. López-Muñoz F., Álamo C. The consolidation of neuroleptic therapy: Janssen, the discovery of haloperidol and its introduction into clinical practice. Brain Research Bulletin 2009, 79:130-141.
49. López-Muñoz F., Álamo C. Monoaminergic neurotransmission: the history of the discovery of antidepressants from 1950s until today. Current Pharmaceutical Design 1950, 15:1563-1586.
50. López-Muñoz F., Álamo C. Historical evolution of the neurotransmission concept. Journal of Neural Transmission 2009, 116:515-533.
51. López-Muñoz, F., Álamo, C., & Cuenca, E. (2000, September). La "Década de Oro" de la Psicofarmacología (1950-1960): Trascendencia histórica de la introducción clínica de los psicofármacos clásicos. Psiquiatria.COM (electronic journal), 4 (3). Available at URL: http://www.psiquiatria.com/psiquiatria/revista/47/1800/%3F++interactivo.
52. López-Muñoz F., Álamo C., Rubio G., Cuenca E. Half a century since the clinical introduction of chlorpromazine and the birth of modern psychopharmacology. Progress in Neuro-Psychopharmacology & Biological Psychiatry 2004, 28:205-208.
53. López-Muñoz F., Álamo C., Cuenca E. Historia de la Psicofarmacología. Tratado de Psiquiatría 2005, 1709-1736. Ars Medica, Barcelona. J. Vallejo, C. Leal (Eds.).
54. López-Muñoz F., Álamo C., Cuenca E., Shen W.W., Clervoy P., Rubio G. History of the discovery and clinical introduction of chlorpromazine. Annals of Clinical Psychiatry 2005, 17:113-135.
55. López-Muñoz F., Álamo C., Juckel G., Assion H.J. Half a century of antidepressant drugs. On the clinical introduction of monoamine oxidase inhibitors, tricyclics and tetracyclics. Part I: Monoamine oxidase inhibitors. Journal of Clinical Psychopharmacology 2007, 27:555-559.
56. López-Muñoz F., Ramchandani D., Álamo C., Cuenca E. Aproximación histórica al descubrimiento del meprobamato y su introducción en psiquiatría: medio siglo de terapéutica ansiolítica. Archivos de Psiquiatría 2005, 68:103-122.
57. López-Muñoz F., Ucha-Udabe R., Álamo C. The history of barbiturates a century after their clinical introduction. Neuropsychiatric Disease and Treatment 2005, 1:329-343.
58. Maddaloni M.A., Hoffman R.S., Wipfler M.G., Weisman R.S. The effect of the triplicate benzodiazepine prescription-regulation on sedative-hipnotic overdoses. Veterinary & Human Toxicology 1990, 32:355.
59. Möhler H., Okada T. Benzodiazepine receptors. Demonstration in the central nervous system. Science 1977, 198:849-851.
60. Norton A. Depression. British Medical Journal 1979, ii:429-430.
61. Nuss P., Sanger D. Ansiolíticos (II). La consolidación de la era ansiolítica: el desarrollo y la introducción clínica de las benzodiazepinas. Historia de la Psicofarmacología 2007, 808-824. Editorial Médica Panamericana, Madrid. F. López-Muñoz, C. Álamo (Eds.).
62. Parish J. The prescribing of psychotropic drugs in general practice. Journal of the Royal College of General Practitioners 1971, 21(Suppl. 4):1-77.
63. Pichot P. History of the treatment of anxiety. Handbook of anxiety, vol. 4. The treatment of anxiety 1990, 3-25. Elsevier Science Publishers BV, Amsterdam. R. Noyes, M. Roth, G.D. Burrows (Eds.).
64. Polc P., Mohler H., Haefely W. The effect of diazepam on spinal cord activities: possible sites and mechanisms of action. Naunyn Schmiedeberg's Archives of Pharmacology 1974, 284:319-337.
65. Rado E. Legislative regulation of benzodiazepinas. American Journal of Forensic Psychiatry 1989, 10:41-49.
66. Ramchandani D., López-Muñoz F., Álamo C. Meprobamate: Tranquilizer or anxiolytic? A historical perspective. Psychiatric Quarterly 2006, 77:43-53.
67. Randall L.O. Pharmacology of methaminodiazepoxide. Diseases of Nervous System 1960, 21(Suppl. 3):7-10.
68. Randall L.O. Discovery of benzodiazepines. Pharmacology of benzodiazepines 1983, 15-21. Verlag Chemie, Deerfield Beech. E. Usdin, P. Skolnick, J.F. Tallman, D. Greenblatt, M. Paul (Eds.).
69. Randall L.O., Schallek W., Heise G.A., Keith E.F., Bagdon R.E. The psychosedative properties of methaminodiazepoxide. Journal of Pharmacology and Experimental Therapy 1960, 129:163-171.
70. Richards G., Schoch P., Haefely W. Benzodiazepine receptors: new vistas. Seminars in Neuroscience 1991, 3:191-204.
71. Rickels K. Use of antianxiety agents in anxious outpatients. Psychopharmacology 1978, 58:1-17.
72. Rickels K. Benzodiazepines: clinical use patterns. Benzodiazepines: a review of research results, NIDA Research Monograph 33 1980, 43-60. Department of Health and Human Services, Washington, D.C.
73. Rickels K., Cattell R., MacAfee A., Hesbacher P. Drug response and important external events in the patient's life. Diseases of Nervous System 1965, 26:782-786.
74. Rickels K., Cattell R.B., Weise C., Gray B., Yee R., Mallin A., et al. Controlled psychopharmacological research in private psychiatric practice. Psychopharmacologia 1966, 9:288-306.
75. Roberts E., Frankel S. Gamma-aminobutyric acid in brain: its formation from glutamic acid. Journal of Biological Chemistry 1950, 187:55-63.
76. Schmidt R.F., Vogel M.E., Zimmermann M. Die Wirkung von Diazepam auf die präsynaptische Hemmung und andere Rückenmarksreflexe. Naunyn Schmiedeberg's Archiv für Pharmakologie und Experimentelle Pathologie 1967, 258:69-82.
77. Serfaty M., Marteston G. Fatal poisonings attributed to benzodiazepines in Britain during the 1980s. British Journal of Psychiatry 1993, 163:386-393.
78. Shader R.I., Greenblatt D.J., Balter M.B. Appropriate use and regulatory control of benzodiazepines. Journal of Clinical Pharmacology 1991, 31:781-784.
79. Sternbach L.H. The discovery of Librium. Agents & Actions 1972, 2:193-196.
80. Sternbach L.H. The benzodiazepine story. Journal of Medicinal Chemistry 1979, 22:1-7.
81. Sternbach L.H., Reeder E. Quinazolines and 1,4-benzodiazepines. II. The rearrangement of 6-chloro-2-chloromethyl-4-phenylquinazoline 3-oxide into 2-amino derivatives of 7-chloro-5-phenyl-3H-1,4-benzodiazepine 4-oxide. Journal of Organic Chemistry 1961, 26:1111-1118.
82. Sternbach L.H., Reeder E. Quinazolines and 1,4-benzodiazepines. IV. Transformation of 7-chloro-2-methylamino-5-phenyl-3H-1,4-benzodiazepine 4 oxide. Journal of Organic Chemistry 1961, 26:4936-4941.
83. Tobin J.M., Bird I.F., Boyle D.E. Preliminary evaluation of Librium (Ro-5-0690) in the treatment of anxiety reactions. Diseases of Nervous System 1960, 21(Suppl. 3):11-19.
84. Tyrer P. The benzodiazepine bonanza. The Lancet 1974, ii:709-710.
85. Tyrer P. Risks of dependence on benzodiazepine drugs: the importance of patient selection. British Medical Journal 1989, 298:102-105.
86. Uhlenhuth E.H., Rickels K., Fisher S., Park L.C., Lipman R.S., Mock J. Drug, doctor's verbal attitude and clinic setting in the symptomatic response to pharmacotherapy. Psychopharmacologia 1966, 9:392-418.
87. Venault, P., & Chapouthier, G. (2007). Neurotransmisión GABAérgica y trastornos de ansiedad: Un enfoque histórico. In: F. López-Muñoz & C. Álamo (Eds.), Historia de la Psicofarmacología (pp. 543-562). Madrid: Editorial Médica Panamericana.
88. Winokur A., Rickels K., Grenblatt D.J., Snyder P.J., Schatz N.J. Withdrawal reaction from long-term, low-dosage administration of diazepam: a double-blind, placebo-controlled case study. Archives of General Psychiatry 1980, 37:101-105.
89. Woodward S.B. Observations on the medical treatment of insanity (1846). American Journal of Psychiatry 1994, 151(Suppl. 6):220-230.